The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).
 
Mahesh Swaminathan
Consulting or Advisory Role - AstraZeneca; Pharmacyclics
 
Courtney Denton Dinardo
Honoraria - Abbvie; Astellas Pharma; Bristol Myers Squibb Foundation; Cleave Biosciences; Foghorn Therapeutics; Genentech/Abbvie; Genmab; Gilead Sciences; GlaxoSmithKline; Jazz Pharmaceuticals; Novartis; Schrodinger; SERVIER
Consulting or Advisory Role - Abbvie; Agios; Celgene; GlaxoSmithKline
Research Funding - Abbvie; Astex Pharmaceuticals; Celgene; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Jazz Pharmaceuticals; Loxo/Lilly; SERVIER
 
Abhishek Maiti
Research Funding - Celgene (Inst); Lin BioScience (Inst)
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASCO; ASH
Consulting or Advisory Role - Abbvie; Aplastic Anemia and MDS International Foundation; Aptitude Health; Astellas Pharma; Blueprint Medicines; Bristol Myers Squibb; CancerNet; CareDx; Celgene; Cimeio Therapeutics; Clearview Healthcare Partners; CTI BioPharma Corp; Curio Science; Dava Oncology; EUSA Pharma; Harborside Press; Imedex; Immunogen; Intellisphere; Intellisphere; Magdalen Medical Publishing; Medscape; Menarini Group; Neopharm; Novartis; OncLive; Pacylex; Patient Power; Peerview; Pharmaessentia; Physicans' Education Resource
Research Funding - US DOD (Inst)
Other Relationship - Karger Publishers
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times
 
Maro Ohanian
Consulting or Advisory Role - Charter Oak Field Services; Dedham Group; Reckner Healthcare
Patents, Royalties, Other Intellectual Property - Pleco Therapeutics
 
Naval Guastad Daver
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; SERVIER; Shattuck Labs; Stemline/Menarini; Syndax; Trillium Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); FATE Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immunogen (Inst); Kite, a Gilead company (Inst); Novimmune (Inst); Pfizer (Inst); Servier (Inst); Trillium Therapeutics (Inst); Trovagene (Inst)
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis
 
Ghayas C. Issa
Consulting or Advisory Role - Kura Oncology; Novartis
Research Funding - Kura Oncology (Inst); Novartis (Inst); Syndax (Inst)
 
Gautam Borthakur
Consulting or Advisory Role - Abbvie; Argenx; BiolineRx; BioTheryX; Catamaran Bio; Nkarta; Novartis; PTC Therapeutics; Takeda; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Arvinas (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BiolineRx (Inst); BioTheryX (Inst); Bristol-Myers Squibb (Inst); Cellestia Biotech (Inst); Cyclacel (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Scientific Affairs (Inst); Lilly (Inst); MedImmune (Inst); Mundipharma Research (Inst); Nkarta (Inst); Nkarta (Inst); Novartis (Inst); Oncoceutics (Inst); PTC Therapeutics (Inst); Ryvu Therapeutics (Inst); TCR2 Therapeutics (Inst); Treadwell Therapeutics (Inst); XBiotech (Inst)
 
Farhad Ravandi-Kashani
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Jazz Pharmaceuticals; Novartis; Pfizer; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Certara Inc; Jazz Pharmaceuticals; Syros Pharmaceuticals; Taiho Oncology
Research Funding - Amgen; Astellas Pharma (Inst); Astex Pharmaceuticals; Biomea Fusion; Bristol-Myers Squibb; Cellerant; Macrogenics; Prelude Therapeutics; Selvita; Syros Pharmaceuticals; Taiho Oncology; Xencor
 
Guillermo Montalban-Bravo
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Genentech (Inst); Gilead Sciences (Inst); Novartis (Inst)
 
Tapan M. Kadia
Honoraria - CURE
Consulting or Advisory Role - Abbvie/Genentech; Agios; Daiichi Sankyo/UCB Japan; Jazz Pharmaceuticals; Liberum; Novartis; Pfizer; Pinot Bio; Sanofi; SERVIER
Research Funding - Amgen; Ascentage Pharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; BiolineRx; Bristol-Myers Squibb; Celgene; cellenkos; Cyclacel; Delta-Fly Pharma; Genentech/Abbvie; Genfleet Therapeutics; Glycomimetics; Incyte; Iterion Therapeutics; Jazz Pharmaceuticals; Pfizer; Pulmotech; Regeneron (Inst)
 
Yesid Alvarado Valero
Honoraria - Astellas Pharma
Consulting or Advisory Role - MEI Pharma
Research Funding - Astex Pharmaceuticals (Inst); BerGenBio (Inst); Daiichi Sankyo/Lilly (Inst); FibroGen (Inst); Jazz Pharmaceuticals (Inst); Sun Pharma (Inst)
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Pfizer; Takeda
 
Nicholas James Short
Honoraria - Amgen
Consulting or Advisory Role - Amgen; AstraZeneca; NGM Biopharmaceuticals; Novartis; Pfizer; Takeda
Research Funding - Astellas Pharma; Stemline Therapeutics; Takeda
 
William G. Wierda
Consulting or Advisory Role - Sanofi
Research Funding - Abbvie; Acerta Pharma; Bristol-Myers Squibb; Cyclacel; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Kite, a Gilead company; Loxo; MDACC Cancer Center Support Grant; NIH/NCI award number CA016672; Novartis; Numab; Nurix; Oncternal Therapeutics, Inc; Pharmacyclics; Xencor
 
Nitin Jain
Honoraria - Abbvie/Genentech; Adaptive Biotechnologies; Adaptive Biotechnologies; ADC Therapeutics; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; MingSight; NovalGen; Pfizer; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Consulting or Advisory Role - Abbvie/Genentech; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; MingSight; NovalGen; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); ADC Therapeutics (Inst); Aprea Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Celgene (Inst); Cellectis (Inst); CRC Oncology (Inst); Dialectic Therapeutics (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); KisoJi Biotechnology (Inst); Kite, a Gilead company (Inst); Loxo/Lilly (Inst); Medisix Therapeutics (Inst); Medisix Therapeutics (Inst); MingSight (Inst); Newave Pharmaceutical (Inst); NovalGen (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Precision Biosciences (Inst); Sana Biotechnology (Inst); SERVIER (Inst); Takeda (Inst); TransThera Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - CRLF2 Bispecific antibody
 
Steven Mitchell Kornblau
No Relationships to Disclose
 
Hagop M. Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Astellas Pharma; AstraZeneca/MedImmune; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; Jazz Pharmaceuticals (Inst); KAHR Medical; Novartis; Pfizer; Precision Biosciences; Shenzhen Target Rx; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
 
Marina Konopleva
Honoraria - Abbvie; Amgen; Forty Seven; Genentech; Roche; Stemline Therapeutics
Consulting or Advisory Role - AbbVie; Amgen; AstraZeneca; Forty Seven; Genentech/Roche; Gilead/Forty Seven; Janssen; MEI Pharma; Roche; Sanofi/Aventis; Stemline Therapeutics; Vincerx Pharma
Research Funding - Abbvie (Inst); Ablynx (Inst); Allogene Therapeutics; AstraZeneca (Inst); Cellectis (Inst); Daiichi Sankyo/Lilly; Forty Seven (Inst); Genentech (Inst); Gilead/Forty Seven; Immunogen; MEI Pharma; Precision Biosciences; Rafael Pharmaceuticals; Sanofi (Inst); Stemline Therapeutics
Patents, Royalties, Other Intellectual Property - Reata pharmaceutical - Research Funding- (Issued, Licensed, Royalities)